Thymosin Alpha-1 is a 28-amino-acid immune-signaling peptide, marketed internationally as thymalfasin under the brand name Zadaxin and approved in more than thirty countries for indications such as chronic hepatitis B and C. It has never received US Food and Drug Administration approval for any use, and the agency placed it on its Category 2 list of bulk drug substances that may not be used in pharmacy compounding. The supporting evidence ranges widely, from reasonably designed hepatitis trials to smaller or inconsistent results elsewhere, which is why its regulatory status and evidence quality matter more than the marketing that surrounds it.
Thymosin Alpha-1 is approved as thymalfasin in more than thirty countries for indications including chronic hepatitis B and C, but it holds no FDA approval in the United States and sits on the FDA's Category 2 list of bulk substances barred from pharmacy compounding.
Despite the name, Thymosin Alpha-1 is not exclusive to the thymus. It is one fragment of a much larger intracellular precursor, prothymosin alpha, which is expressed in nearly all tissues and cleaved by proteolytic enzymes to release the 28-amino-acid peptide. The thymus earns its place in the name for historical reasons: it is where T-lymphocytes mature, and 1970s researchers fractionating a crude thymic extract called thymosin fraction 5 first isolated the molecule.
Thymosin Alpha-1 is a 28-amino-acid peptide cleaved from the widely expressed precursor prothymosin alpha, and the modern therapeutic product is made by chemical synthesis to a defined sequence rather than extracted from thymic tissue.
Thymosin Alpha-1 carries no meaningful direct antiviral or antitumor action of its own; its effects are entirely immune-mediated, so it depends on a host immune system able to respond. It acts as a pleiotropic modulator, nudging several parts of the immune system at once rather than hitting a single target, with much of its signaling thought to run through pattern-recognition receptors on dendritic and other immune cells.
Thymosin Alpha-1 has no direct antiviral or antitumor activity of its own and works entirely through the immune system, signaling largely via Toll-like receptors to mature immune cells and shift cytokine production toward a T-helper-1 profile.
The clinical footprint is broad but uneven, reflecting a general immune modulator rather than a targeted drug. The most established use anchors most of its national approvals, while the rest thins out into adjunct and investigational territory. One distinction holds across all of it: even where it is an approved product abroad, none of these uses is FDA-approved in the United States.
The most established use of Thymosin Alpha-1 is chronic viral hepatitis B and C, the indication behind most of its national approvals, while its roles in vaccine response, sepsis, and cancer remain adjunctive or investigational and are not FDA-approved in the United States.
The legal status splits sharply between the United States and most of the rest of the world, and that gap is the single most important point for a reader to grasp. In the US the peptide is not FDA-approved for any indication, has no marketed agency-reviewed product, and after review as a nominated bulk substance was placed in compounding Category 2, so for practical purposes it cannot be legally compounded.
| Criteria | United States | Most of the world |
|---|---|---|
| Approval | Not FDA-approved for any indication | Thymalfasin approved in 30+ countries |
| Compounding | Category 2, not legally compoundable | Not applicable; sold as a finished drug |
| Typical indications | None recognized | Chronic hepatitis B and C, immune adjuvant |
| Legal supply route | None; only a research-chemical gray market | Pharmacy and hospital dispensing |
Thymosin Alpha-1 is not FDA-approved for any indication and sits in compounding Category 2 in the United States, meaning there is no legal, quality-assured route to obtain it domestically, even though thymalfasin is an approved medicine in more than thirty other countries.
The honest summary is a plausible mechanism with genuinely promising hepatitis data and generally weaker, less consistent evidence everywhere else. Enthusiasm often outpaces the certainty the data can support, largely because much of the literature is small, single-region, or industry-adjacent.
The evidence for Thymosin Alpha-1 is strongest in chronic viral hepatitis, where decades of randomized trials suggest improved sustained viral response as an add-on therapy, while its data in sepsis, cancer, and vaccine adjuvant use remain smaller, mixed, and less consistent.
In the controlled trials behind its approved uses, Thymosin Alpha-1 shows a generally favorable safety profile, with most complaints being mild and local at the injection site and serious drug-attributable events reported infrequently. That picture comes from monitored studies of a defined pharmaceutical product, not from the unverified vials sold outside pharmaceutical oversight, and the risk profile shifts with the situation.
The approved pharmaceutical form of Thymosin Alpha-1 is generally well tolerated with mostly mild injection-site reactions, but caution is documented in autoimmune disease, immunosuppression, transplantation, and pregnancy, and gray-market vials carry added risks of contamination, mislabeling, and inaccurate dosing.
Thymosin Alpha-1 is given by subcutaneous injection because, as a peptide, it would be broken down if taken orally. The figures below describe how the approved product has been studied and used abroad, mainly in hepatitis; they are not a self-administration protocol, and exact regimens vary by country, indication, and the clinician's protocol.
In its established hepatitis use, thymalfasin has commonly been dosed at 1.6 milligrams by subcutaneous injection twice weekly over a course of six months or longer, often combined with interferon or antiviral therapy and overseen by a physician.
Although wellness discussions group them together, Thymosin Alpha-1 differs fundamentally from the peptides it gets compared to. Thymosin Beta-4 shares only the thymosin name, thymalin and older thymic extracts are crude mixtures rather than a defined molecule, and interferons are potent direct-acting cytokines, whereas Thymosin Alpha-1 works upstream by helping immune cells mature and coordinate.
| Criteria | Thymosin Alpha-1 | Thymosin Beta-4 | Interferons |
|---|---|---|---|
| Structure | 28-amino-acid defined peptide | Unrelated 43-amino-acid peptide | Cytokine proteins |
| Main biology | Immune-cell maturation | Actin regulation, tissue repair | Direct antiviral action |
| Mode of action | Indirect, immune-mediated | Wound healing, angiogenesis | Potent, direct-acting |
| Side-effect burden | Generally light | Not established clinically | Heavier |
Thymosin Alpha-1 differs fundamentally from the peptides it is grouped with, working indirectly to mature and coordinate immune cells, unlike the actin-regulating Thymosin Beta-4, crude thymic-extract mixtures such as thymalin, or the direct-acting interferons.
Availability depends entirely on location. Where thymalfasin is approved, it is dispensed as a branded specialty medicine through pharmacies and hospitals and covered to varying degrees for its approved indications; in the United States there is no approved product to buy, and the legal domestic supply narrowed sharply once the peptide was excluded from the compounding list.
In the United States there is no FDA-approved Thymosin Alpha-1 to purchase, so supply comes from a research-chemical gray market pricing vials from tens to low hundreds of dollars, with no insurance coverage, no recourse for defective product, and no regulated route that makes it a quality-assured purchase.
Educational use only. This article describes what the published scientific and clinical literature reports about Thymosin Alpha-1. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
